Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter Baumannii

Authors

Sara Alosaimy
Taylor Morrisette
Abdalhamid M. Lagnf
Leonor M. Rojas
Madeline A. King
Benjamin M. Pullinger
Athena L. V. Hobbs
Nicholson B. Perkins
Michael P. Veve
Jeannette Bouchard
Tristan Gore
Bruce Jones
James Truong
Justin Andrade, Touro College of PharmacyFollow
Glen Huang
Reese Cosimi
S. Lena Kang-Birken
Kyle C. Molina
Mark Biagi
Michael Pierce
Marco R. Scipione
Jing J. Zhao
Susan L. Davis
Michael J. Rybak

Roles

Author

Document Type

Article

Publication Date

1-1-2022

Publication Title

Microbiology Spectrum

DOI

10.1128/spectrum.00479-22

Recommended Citation

Alosaimy, S., Morrisette, T., Lagnf, A. M., Rojas, L. M., King, M. A., Pullinger, B. M., Hobbs, A. L., Perkins, N. B., Veve, M. P., Bouchard, J., Gore, T., Jones, B., Truong, J., Andrade, J., Huang, G., Cosimi, R., Kang-Birken, S. L., Molina, K. C., Biagi, M., Pierce, M., Scipione, M. R., Zhao, J. J., Davis, S. L., & Rybak, M. J. (2022). Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter Baumannii. Microbiology Spectrum, 10 (5), e0047922. https://doi.org/10.1128/spectrum.00479-22